SCRIBE THERAPEUTICS INC. Deferred Revenue
SCRIBE THERAPEUTICS INC. (SCTX) had Deferred Revenue of $27.48 million as of 2026-06-30, per its 10-Q filed 2026-09-02.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2026-09-02
- 2026-06-30: Deferred Revenue, Current $27.48M.
- 2025-12-31: Deferred Revenue, Current $21.09M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2026-06-30 | $27.48M 10-Q · filed 2026-09-02 |
| 2025-12-31 | $21.09M 10-Q · filed 2026-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |